ArticleSchizophrenia research2014
A controlled family study of cannabis users with and without psychosis.
Article in Schizophrenia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 55 citations in OpenAlex.
- Long-term use of cannabis-based medicines in two children with Tourette syndrome: a case report.Frontiers in psychiatry · 2025Article
- A bibliometric analysis of the cannabis and cannabinoid research literature.Journal of cannabis research · 2022Article
- Δ-9-Tetrahydrocannabinol treatment during adolescence and alterations in the inhibitory networks of the adult prefrontal cortex in mice subjected to perinatal NMDA receptor antagonist injection and to postweaning social isolation.Translational psychiatry · 2020Article
- The Role of Cannabis within an Emerging Perspective on Schizophrenia.Medicines (Basel, Switzerland) · 2018Article
- Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins.Schizophrenia bulletin · 2017Article
- Building smart cannabis policy from the science up.The International journal on drug policy · 2017Review
- Whole-genome sequencing in multiplex families with psychoses reveals mutations in the SHANK2 and SMARCA1 genes segregating with illness.Molecular psychiatry · 2016Article
- Cannabis and Psychosis: a Critical Overview of the Relationship.Current psychiatry reports · 2016Review
- Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Article
- Cannabinoids for the Treatment of Movement Disorders.Current treatment options in neurology · 2015Article
- Medical marijuana: Between a plant and a hard place.Neurology. Clinical practice · 2015Article
- Prenatal marijuana exposure, age of marijuana initiation, and the development of psychotic symptoms in young adults.Psychological medicine · 2015Article
- Pursuit of the "truth" about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past.Dialogues in clinical neuroscience · 2014Article
- Re: Caution urged in interpreting a negative study of cannabis use and schizophrenia: a response to Dr. Christine Miller.Schizophrenia research · 2014Article
- The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.Frontiers in psychiatry · 2014Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCannabis is one of the most highly abused illicit drugs in the world. Several studies suggest a link between adolescent cannabis use and schizophrenia. An understanding of this link would have significant implications for legalization of cannabis and its medicinal value. The present study aims to determine whether familial morbid risk for schizophrenia is the crucial factor that underlies the association of adolescent cannabis use with the development of schizophrenia.
methodsConsecutively obtained probands were recruited into four samples: sample 1: 87 non-psychotic controls with no drug use; sample 2: 84 non-psychotic controls with cannabis use; sample 3: 32 patients with a schizophrenia spectrum psychosis with no drug use; sample 4: 76 patients with schizophrenia spectrum psychosis with cannabis use. All cannabis using subjects used this drug during adolescence, and no other substance, with the exception of alcohol. Structured interviews of probands and family informants were used to obtain diagnostic information about probands and all their known relatives.
resultsThere was an increased morbid risk for schizophrenia in relatives of the cannabis using and non-using patient samples compared with their respective non-psychotic control samples (p=.002, p<.001 respectively). There was no significant difference in morbid risk for schizophrenia between relatives of the patients who use or do not use cannabis (p=.43).
conclusionsThe results of the current study suggest that having an increased familial morbid risk for schizophrenia may be the underlying basis for schizophrenia in cannabis users and not cannabis use by itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.